NFL Biosciences SA

Paris Stock Exchange ALNFL.PA

NFL Biosciences SA Price to Earnings Ratio (P/E) on January 14, 2025: -4.51

NFL Biosciences SA Price to Earnings Ratio (P/E) is -4.51 on January 14, 2025, a -35.10% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • NFL Biosciences SA 52-week high Price to Earnings Ratio (P/E) is -2.96 on January 22, 2024, which is 34.39% above the current Price to Earnings Ratio (P/E).
  • NFL Biosciences SA 52-week low Price to Earnings Ratio (P/E) is -6.48 on March 20, 2024, which is -43.92% below the current Price to Earnings Ratio (P/E).
  • NFL Biosciences SA average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.77.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Paris Stock Exchange: ALNFL.PA

NFL Biosciences SA

CEO Dr. Ignacio Faus M.B.A., Ph.D.
IPO Date July 5, 2021
Location France
Headquarters 199 Rue Helene Boucher
Employees 4
Sector Health Care
Industries
Biotechnology Pharmaceuticals Tobacco
Description

NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

Similar companies

ABNX.PA

ABIONYX Pharma SA

USD 1.29

-1.75%

StockViz Staff

January 15, 2025

Any question? Send us an email